FDA’s Root Cause Investigation Into Bupropion Trouble Could Have Broad Implications For Generics
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency is now turning to outside researchers for studies to determine why Impax and Teva’s 300 mg bupropion generic failed and what that might mean for generics as a whole.